Loading...
India's magnesium imports from CHINA total $600 across 2 shipments from 1 foreign suppliers. SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. leads with $600 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include VIMTA LABS LIMITED. This corridor reflects India's pharmaceutical import demand for magnesium — a concentrated sourcing relationship with select suppliers from CHINA.
SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. is the leading Magnesium supplier from CHINA to India, with import value of $600 across 2 shipments. The top 5 suppliers — SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. | $600 | 2 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | VIMTA LABS LIMITED | $600 | 2 | 100.0% |
CHINA → India trade corridor intelligence
As of April 2026, the China to India pharmaceutical import corridor for finished magnesium formulations is operating with an average sea transit time of 14 days and air transit time of 7 days. Approximately 80% of shipments are transported by sea, while 20% are by air. There are no significant reports of port congestion at major Indian ports such as Jawaharlal Nehru Port (JNPT), Chennai, or Mundra. Freight rates have remained stable over the past year, and the exchange rate between the Indian Rupee (INR) and the Chinese Yuan (CNY) has shown minimal fluctuation, ensuring predictable costs for importers.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce reliance on imports, including finished pharmaceutical formulations. While the PLI scheme has led to increased domestic production capabilities, the demand for specialized magnesium formulations continues to necessitate imports. Import substitution policies are being evaluated to identify areas where domestic production can be enhanced, but the transition is gradual, and imports from countries like China remain essential to meet current market needs.
India and China maintain a complex trade relationship, with ongoing discussions to enhance cooperation in various sectors, including pharmaceuticals. While there are no specific Free Trade Agreements (FTAs) between the two countries, both have engaged in dialogues to address trade barriers and facilitate smoother trade flows. Mutual recognition of Good Manufacturing Practices (GMP) is a topic of interest, aiming to streamline regulatory processes and ensure product quality. These bilateral efforts are focused on enhancing trade facilitation and addressing challenges in the pharmaceutical sector.
For a shipment of finished pharmaceutical formulations containing magnesium under HS Code 30049099, the estimated landed cost from China to India is calculated as follows:
Total Landed Cost per Unit: $139.42
These estimates are subject to change based on fluctuations in freight rates, exchange rates, and any changes in duty structures.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing magnesium into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs, including those under HS Code 30049099, obtain an Import Registration Certificate and an Import License. The registration process involves submitting Form 40 or 41 to CDSCO, along with necessary documents such as the Free Sale Certificate, Certificate of Pharmaceutical Product (CoPP), and stability data. The timeline for registration can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory workload. Additionally, a No Objection Certificate (NOC) from the State Drug Controller is required for the importation of drugs. These requirements ensure that imported formulations meet India's quality, safety, and efficacy standards.
Imported pharmaceutical formulations containing magnesium must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, is also mandatory to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity of documents and the quality of the products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or additional costs for the importer.
In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including those under HS Code 30049099. This move aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy mandates that drugs manufactured in Special Economic Zones (SEZs) for export purposes cannot be transferred to the Domestic Tariff Area (DTA) for sale and distribution. Additionally, for unapproved and approved new drugs manufactured in SEZs, compliance with the requirements specified under the New Drugs and Clinical Trials Rules, 2019, and the Drugs Rules, 1945, is necessary. These regulatory updates are designed to streamline the import process and ensure that imported formulations meet India's stringent quality standards.
Market demand, customs duty structure, and competitive landscape · Import duty: 17.10%
India imports finished pharmaceutical formulations containing magnesium to meet the demand for specific dosage forms and formulations not produced domestically. This includes patented or branded products, specialized dosage forms, and formulations that require advanced manufacturing technologies. The total market size for magnesium formulations in India is substantial, with imports playing a crucial role in fulfilling the unmet demand. The reliance on imports is due to factors such as the need for specialized formulations, quality standards, and the inability of domestic manufacturers to produce certain magnesium-based products.
The import duty structure for finished pharmaceutical formulations containing magnesium under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Integrated Goods and Services Tax (IGST) of 12%, and a Social Welfare Surcharge (SWS) of 10%. This results in a total landed duty of approximately 17.10%. There are no additional duties such as the National Calamity Contingent Duty (NCCD) or Anti-Dumping Duty applicable to this product category. Importers should also be aware of any exemptions or concessional rates that may apply under specific trade agreements or government notifications.
China's competitive position as a source of finished pharmaceutical formulations containing magnesium for India is influenced by factors such as cost-effectiveness, manufacturing capabilities, and the ability to produce specialized formulations. Chinese manufacturers often offer competitive pricing and have the capacity to produce a wide range of formulations, including those not readily available from other suppliers. While other countries like Germany and the United States also supply these formulations, China's market share remains significant due to its established manufacturing infrastructure and export experience.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished pharmaceutical formulations containing magnesium from China due to several strategic reasons:
When comparing China to other origins such as the European Union and the United States as sources for finished pharmaceutical formulations containing magnesium, several factors come into play:
China's unique advantage lies in its ability to offer a wide range of formulations at competitive prices, making it a preferred source for many Indian importers.
Indian importers face several supply chain risks when sourcing finished pharmaceutical formulations containing magnesium from China:
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Magnesium suppliers from CHINA to India include SHANDONG NEW TIME PHARMACEUTICAL CO., LTD.. The leading supplier is SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. with import value of $600 USD across 2 shipments. India imported Magnesium worth $600 USD from CHINA in total across 2 shipments.
India imported Magnesium worth $600 USD from CHINA across 2 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Magnesium sourced from CHINA include VIMTA LABS LIMITED. The largest buyer is VIMTA LABS LIMITED with $600 in imports across 2 shipments.
The total value of Magnesium imports from CHINA to India is $600 USD, across 2 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists